Product
Remaxol
Aliases
inosine + meglumine + methionine + nicotinamide + succinic acid
3 clinical trials
6 indications
Indication
CholestasisIndication
IntrahepaticIndication
CancerIndication
Drug-Induced Liver InjuryIndication
Gallstone DiseaseIndication
Obstructive JaundiceClinical trial
Multicenter Comparative Randomized Study to Assess Safety and Efficacy and Select the Optimal Dosage Regimen of REMAXA®, Enteric-coated Tablets, in Comparison With REMAXOL®, Solution for Infusions, in Patients With Intrahepatic Cholestasis Caused by Chronic Diffuse Liver DiseasesStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Non-interventional, Prospective Study of Safety and Efficiency of the Drug Remaxol® (NTFF POLYSAN Ltd., Russia) in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy.Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Observational Study of Efficiency of the Drug Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive JaundiceStatus: Recruiting, Estimated PCD: 2023-12-01